The FDA is currently reviewing Summit's PD-1/VEGF bispecific as part of a chemotherapy combo for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer.
Zacks Investment Research on MSN
Merck's non-oncology drugs Q4 performance: What to expect
As Merck MRK is gearing up to report its fourth-quarter and full-year 2025 results on Feb. 3, investors' focus is likely to ...
GlobalData on MSN
Moderna’s cancer vaccine plus Keytruda boosts RFS in melanoma study
A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.
Gilead Sciences recently reported in The New England Journal of Medicine that its Phase 3 ASCENT-04/KEYNOTE-D19 trial showed Trodelvy plus Keytruda improved progression-free survival over Keytruda ...
The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...
The Chosun Ilbo on MSN
Obesity treatments overtake Keytruda as top-selling drugs
Obesity treatments are reshaping the global pharmaceutical and biotech market landscape. Recent preliminary figures show that ...
Merck’s MRK blockbuster PD-L1 inhibitor, Keytruda, approved for several types of cancer indications, is the company's biggest revenue driver. The drug alone accounts for around 50% of the company’s ...
Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results